Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01403064 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects
A Phase 2 study, sponsored by CSL Behring.
- Terminated
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT01403064 is a Phase 2 study that was terminated before completion, run by CSL Behring. The registered enrollment target is 76 participants.
The verdict
NCT01403064, a Phase 2 study, was terminated before completion, sponsored by CSL Behring.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy
Interventions
- DRUG 0.9% saline
- BIOLOGICAL ALD518
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01403064
The ClinicalTrials.gov registry entry for NCT01403064 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 0.9% saline is the first listed.
NCT01403064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01403064 about?
NCT01403064 is a clinical study titled "Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects". The purpose of this study is to evaluate the safety and efficacy of ALD518 in modifying the course of oral mucositis in subjects with head and neck cancer receiving concomitant chemotherapy and radiotherapy
What is the current status of trial NCT01403064?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2011-07. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01403064?
The interventions under investigation include: 0.9% saline (DRUG), ALD518 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01403064?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.